Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Pharmaceuticals & Biotechnology | Small Cap
Health Score : 4.16Krebs Biochemicals & Industries Ltd, operating in the Healthcare Services sector, shows a mixed financial performance. The company exhibits strengths in solvency, efficiency, and growth, but struggles with liquidity, coverage, financial metrics, and profitability. While the company showcases good performance in managing its debts and generating profits from its operations, it faces challenges in meeting its short-term obligations and ensuring consistent revenue growth. The negative profitability margins and low coverage ratios raise concerns about the company's financial sustainability. Overall, the company needs to address its liquidity and profitability issues to improve its financial health and stability.
Health Score : 4.16Krebs Biochemicals & Industries Ltd, operating in the Healthcare Services sector, shows a mixed financial performance. The company exhibits strengths in solvency, efficiency, and growth, but struggles with liquidity, coverage, financial metrics, and profitability. While the company showcases good performance in managing its debts and generating profits from its operations, it faces challenges in meeting its short-term obligations and ensuring consistent revenue growth. The negative profitability margins and low coverage ratios raise concerns about the company's financial sustainability. Overall, the company needs to address its liquidity and profitability issues to improve its financial health and stability.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
-4.27
Industry Median
30.91
Small Cap Median
28.64
P/E RATIO
-4.36
P/B RATIO
-0.74
Industry Median
3.69
Small Cap Median
3.11
P/S RATIO
2.74
Industry Median
3.74
Small Cap Median
3.02
Others
PEG RATIO
-3.54
EV/EBITDA RATIO
-20.04
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹54.49 as on Sep 1, 2026.
Growth Score : 7.20The company exhibits strong growth in operating profit, EPS, and net income, but revenue and assets have declined. This suggests improved profitability despite revenue challenges. The company's ability to grow profits faster than revenue indicates enhanced operational efficiency. However, declining revenue and assets raise concerns about sustainability. Focus on revenue generation and asset growth is essential for long-term success.
Revenue Growth RatePoorOperating Profit Growth RateExcellentEarnings Per Share (EPS) GrowthExcellentAsset Growth RatePoorNet Income Growth RateExcellent| Growth Ratios | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 63.64 | 11.11 | -13.33 | -3.85 | -14 |
| Operating Profit Growth Rate | 5.26 | -88.89 | 52.94 | 43.75 | -66.67 |
| Earnings Per Share (EPS) Growth | 9.91 | -42.91 | 44.55 | 20.09 | -36.61 |
| Asset Growth Rate | 19.5 | -7.89 | 1.71 | -5.06 | |
| Net Income Growth Rate | 3.45 | -60.71 | 44.44 | 20 | -35 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Par Drugs & Chemicals Ltd | 7.40 | 13.20 | Neutral | 17.00 | 10.65 | 13.00 |
| 2 | Vaishali Pharma Ltd | 6.74 | 25.09 | Neutral | 4.00 | 0.31 | 4.00 |
| 3 | Quest Laboratories Ltd | 5.27 | 9.34 | Neutral | 18.00 | 9.16 | 15.00 |
| 4 | Sotac Pharmaceuticals Ltd | 5.27 | 17.25 | Neutral | 18.00 | 4.45 | 6.00 |
| 5 | Zenith Drugs Ltd | 4.63 | 7.41 | Neutral | 17.00 | 2.30 | 10.00 |
| 6 | Krebs Biochemicals & Industries Ltd | 4.16 | -4.36 | Highly Undervalued | -4.00 | -7.85 | -4.00 |
| 7 | PANCHSHEEL | N/A | N/A | N/A | N/A | N/A | N/A |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
No Stock Reports Available at This Moment.
Krebs Biochemicals & Industries Ltd. is an Indian pharmaceutical company specializing in the manufacture of active pharmaceutical ingredients (APIs), bulk drugs, and intermediates through biotechnology and fermentation processes. It serves the global pharmaceutical industry with a focus on cost-effective and high-quality products. The company holds a niche position in fermentation-based biochemicals.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Krebs Biochemicals & Industries Ltd's P/E ratio (TTM) is -4.27, compared to the industry median of 30.91 and large cap median of 28.64.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Krebs Biochemicals & Industries Ltd's P/B ratio is -0.74, compared to the industry median of 3.69 and large cap median of 3.11.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Krebs Biochemicals & Industries Ltd's P/S ratio is 2.74, compared to the industry median of 3.74 and large cap median of 3.02.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Krebs Biochemicals & Industries Ltd's PEG ratio is -3.54.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Krebs Biochemicals & Industries Ltd's EV/EBITDA ratio is -20.04.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Krebs Biochemicals & Industries Ltd's ROE is N/A.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Krebs Biochemicals & Industries Ltd's ROA is -8.88%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Krebs Biochemicals & Industries Ltd's ROCE is -30%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Krebs Biochemicals & Industries Ltd's operating margin is -34.88%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Krebs Biochemicals & Industries Ltd's net margin is -62.79%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Krebs Biochemicals & Industries Ltd's current ratio is 0.13.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Krebs Biochemicals & Industries Ltd's debt-to-equity ratio is -1.10.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Krebs Biochemicals & Industries Ltd's interest coverage ratio is -3.50.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Krebs Biochemicals & Industries Ltd's DPS is ₹0.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Krebs Biochemicals & Industries Ltd's EPS is -36.61.
(Source line: "Ratios as of 25 Sept 2026, based on last traded price of ₹54.49. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1991
Headquarters: Hyderabad, Telangana
Core Offerings: Active Pharmaceutical Ingredients (APIs), Bulk Drugs, Fermentation Products, Contract Manufacturing Services
Stock Listing: NSE (KREBSBIO), BSE (524518)
Promoter: Dr. A. P. Ranga Rao / Rao family
Krebs Biochemicals & Industries Ltd. was incorporated in 1991. The company established itself as a significant player in the biotechnology and pharmaceutical sector, focusing on manufacturing APIs and biochemicals using advanced fermentation technology. Over the years, it has continuously developed its R&D capabilities and production infrastructure to cater to the evolving needs of the global pharmaceutical industry, maintaining a specialized niche in fermentation-based products.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| APIs & Intermediates (Biochemicals) | 100% | N/A (company does not report segment-wise EBITDA) |
The company primarily focuses on a single business segment encompassing biochemicals and pharmaceuticals:
Active Pharmaceutical Ingredients (APIs): Development and manufacturing of various APIs for diverse therapeutic areas, utilizing complex chemical and biochemical synthesis routes.
Fermentation Technology: Leveraging expertise in industrial-scale fermentation processes to produce specialized biochemicals, drug intermediates, and bulk drugs efficiently.
Contract Manufacturing Services (CRAMS): Provides contract manufacturing and research services to other pharmaceutical companies, leveraging its robust infrastructure and R&D capabilities for custom synthesis.
Dr. A. P. Ranga Rao - Chairman & Managing Director. Dr. Rao is the founder of the company and a visionary leader with extensive experience and expertise in the biochemical and pharmaceutical industries.
No major subsidiaries reported.
No major recent corporate actions on record.
The Krebs Biochemicals & Industries Ltd share price today is ₹54.49 on NSE (KREBSBIO), as of 26 Sept 2026.
As of 25 Sept 2026, Krebs Biochemicals & Industries Ltd share price is ₹54.49, with previous close ₹54.49. Today's range is ₹54.49 to ₹54.49. The 52-week range is ₹38.33 to ₹76.85.
As of today, Krebs Biochemicals & Industries Ltd's market cap is ₹117.7 crore (Small Cap).
Krebs Biochemicals & Industries Ltd's current P/E ratio is -4.27, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 34.20.
Krebs Biochemicals & Industries Ltd's current P/B ratio is -0.74.
Krebs Biochemicals & Industries Ltd's current dividend yield is N/A. Last dividend of ₹0.00 per share was declared on N/A.
Krebs Biochemicals & Industries Ltd's EPS (TTM) is ₹-36.61.
Krebs Biochemicals & Industries Ltd. is an Indian pharmaceutical company specializing in the manufacture of active pharmaceutical ingredients (APIs), bulk drugs, and intermediates through biotechnology and fermentation processes. It serves the global pharmaceutical industry with a focus on cost-effective and high-quality products. The company holds a niche position in fermentation-based biochemicals.
Krebs Biochemicals & Industries Ltd is promoted by Dr. A. P. Ranga Rao / Rao family, holding 193.68% as of 25 Sept 2026.
Krebs Biochemicals & Industries Ltd is listed on NSE (KREBSBIO) and BSE (524518). Its next quarterly results are expected on August 2024.
Capital Expenditures (CapEx)
